TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

REIMAGINE THE WAY YOU TREAT HAE

For your patients, what do you want to reimagine with TAKHZYRO?

Sebastian

Real TAKHZYRO patient

TAKHZYRO® injection logo.

Rediscover prevention

  • Significant reduction in mean monthly attacks vs placebo1
  • Secondary endpoints of reduction in moderate or severe attacks and attacks requiring acute treatment vs placebo were met1
  • There were patients who had zero attacks according to an exploratory analysis1,2

The safety and efficacy of TAKHZYRO were assessed in a 26-week clinical trial of 125 HAE patients ≥12 years of age. The primary efficacy endpoint was the rate of investigator-confirmed attacks during the treatment period compared to placebo. Secondary endpoints included the reduction in moderate or severe attacks and attacks requiring acute treatment. The percentage of patients who had zero attacks over the entire 26-week study duration was a prespecified, exploratory endpoint.1,2

Real TAKHZYRO® patient Sebastian. Rediscover prevention with TAKHZYRO®.

Sebastian

Real TAKHZYRO patient

SELECT IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Rethink dosing and administration

One subcutaneous self-injection every 2 weeks1*

*The recommended starting dose is 300 mg every 2 weeks. TAKHZYRO every 4 weeks is also effective and may be considered if the patient is well-controlled (eg, attack free) for more than 6 months.1

Image of a TAKHZYRO® 300 mg/2 mL vial.

Refine the approach

The first and only monoclonal antibody (mAb) for HAE, TAKHZYRO inhibits plasma kallikrein activity1

SEE HOW
TAKHZYRO WORKS
Visual representation of TAKHZYRO®, a monoclonal antibody.

TAKHZYRO
Quick Start
Program

Get patients started
on TAKHZYRO

Takeda will provide eligible patients with immediate access to TAKHZYRO at no cost during potential delays in commercial insurance coverage determinations†

†Timing is dependent upon when the forms are received by OnePath®. The Quick Start Program is available to all commercially insured patients ≥12 years of age who are US residents with a confirmed diagnosis of HAE.
Takeda and its affiliates reserve the right to change or discontinue this program at any time, without notice. Void where prohibited by law. This program does not constitute a financial assistance program.

INDICATION

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1–800–828–2088, or FDA at 1–800–FDA–1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

References: 1. TAKHZYRO (lanadelumab-flyo) [prescribing information]. Lexington, MA: Shire LLC; 2018. 2. Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108-2121.